ABCB5 is an ATP-binding cassette transporter implicated in cancer stem cell maintenance, drug resistance, and immunomodulation . Two primary isoforms exist:
ABCB5FL (full transporter): Expressed in testes/prostate and linked to multidrug resistance.
ABCB5β (half-transporter): Ubiquitously expressed and associated with tumor-initiating cells in melanoma, breast cancer, and other malignancies .
Commercial antibodies target specific ABCB5 epitopes, with applications in Western blot (WB), immunohistochemistry (IHC), and flow cytometry. Key examples include:
Dilutions:
WB: 1:20,000
IHC: 1:200
Validation: Detects ABCB5 in paraffin-embedded tissues (Figure 1) .
Target: Endogenous ABCB5 across human, mouse, and rat samples .
Applications: WB, IHC, immunofluorescence.
Melanoma: ABCB5+ cells exhibit chemoresistance via IL-1β/IL-8 signaling . Knockdown (KD) of ABCB5 in A375/G3361 melanoma models reduced tumor growth by >3-fold in vivo .
Immunomodulation: ABCB5+ dermal mesenchymal cells prolong cardiac allograft survival via PD-1/IL-1RA pathways .
Antibody 3C2-1D12: Blocks ABCB5-mediated drug efflux, sensitizing melanoma cells to chemotherapy .
Peptide Vaccines: ABCB5 extracellular loop 3-derived peptides (e.g., RFGAYLIQAGRMTPEG) induce CD8+ T-cell responses in preclinical models .